Hold Glenmark Pharmaceuticals; target of Rs 470: ICICI Direct
ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 470 in its research report dated November 21, 2022.22-11-2022
22-11-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg22-11-2022
Accumulate Glenmark Pharmaceuticals; target of Rs 460: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 460 in its research report dated November 19, 2022.21-11-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Further to our letter dated 03rd November, 2022 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings call held on Monday, November 14, 2022 for the quarter and half year ended September 30, 2022 has been uploaded on the Company's website18-11-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2022 which is scheduled today at 17:30 IST, in Mumbai. Kindly take the same on record and acknowledge receipt.17-11-2022
Results Earnings Call for Q2FY23 of Glenmark Pharmaceuticals
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.15-11-2022
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Q2 of FY 2022-23 Earnings Call14-11-2022
Q2FY23 Quarterly Result Announced for Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals announced Q2FY23 results: For Q2FY23, Glenmark’s consolidated revenue was at Rs 33,752 million as against Rs 31,474 million, recording an increase of 7.2% Reported EBITDA was at Rs 6,216 million in Q2FY23, as against Rs 5,902 million in the previous corresponding quarter, with a margin of 18.4%, registering an increase of 5.3% Adjusted EBITDA for the quarter was at Rs 6,526 million, with an adjusted EBITDA margin of 19.3%. Profit after Tax (PAT) was at Rs 2,787 million for Q2FY23, as compared to Rs 2,748 million in the previous corresponding quarter, recording a growth of 1.4%. “We delivered yet another quarter of consistent growth, with our relentless focus on launching differentiated products in our core therapeutic areas. Our novel drug Ryaltris™ was launched in the US by our partner Hikma, and our Canadian partner, Bausch Health, received marketing approval from Health Canada with an expected launch during the second half of the financial year. Our India business recorded strong double-digit growth and our Europe business also performed very well in spite of a challenging macro-economic environment,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd. He further added, “We look forward to launching new products across markets and building global scale in our respiratory portfolio. We remain focused in achieving our strategic objectives for the financial year.” Result PDF14-11-2022
Glenmark Pharma Q2 PAT rises marginally to Rs 279 crore
"We delivered yet another quarter of consistent growth, with our relentless focus on launching differentiated products in our core therapeutic areas," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.11-11-2022